Evidence map›Paper›PMID 30273398›Full record

Observational studyPloS one2018

Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.

Georg Richtig, Christoph Hoeller, Martin Wolf, Ingrid Wolf, Barbara M Rainer, Günter Schulter, Markus Richtig, Martin R Grübler, Anna Gappmayer, Thomas Haidn and 7 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Georg RichtigOtto Loewi Research Center, Pharmacology Section, Medical University of Graz, Graz, Austria.ORCID 0000-0002-4437-4413
Christoph HoellerDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Martin WolfDepartment of Dermatology, Medical University of Graz, Graz, Austria.
Ingrid WolfDepartment of Dermatology, Medical University of Graz, Graz, Austria.
Barbara M RainerDepartment of Dermatology, Medical University of Graz, Graz, Austria.
Günter SchulterDepartment of Psychology, Biological Psychology Unit, University of Graz, Graz, Austria.
Markus RichtigDepartment of Dermatology, Medical University of Graz, Graz, Austria.
Martin R GrüblerSwiss Cardiovascular Center Bern, Department of Cardiology, Bern University Hospital, Bern, Switzerland.
Anna GappmayerDepartment of Dermatology, State Hospital Wiener Neustadt, Wiener Neustadt, Austria.
Thomas HaidnDepartment of Dermatology, State Hospital Wiener Neustadt, Wiener Neustadt, Austria.
Julian KoflerDepartment of Dermatology and Venereology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Austria.
Rainer HuegelDepartment of Dermatology and Venereology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Austria.
Bernhard Lange-AsschenfeldtDepartment of Dermatology and Venereology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Austria.
Martin PichlerDivision of Oncology, Medical University Graz, Graz, Austria.
Stefan PilzDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
Akos HeinemannOtto Loewi Research Center, Pharmacology Section, Medical University of Graz, Graz, Austria.
Erika RichtigDepartment of Dermatology, Medical University of Graz, Graz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionImmunotherapy is a well-established treatment option in patients with metastatic melanoma. However, biomarkers that can be used to predict a response in these patients have not yet been found, putting patients at risk of severe side effects.

methodsIn this retrospective analysis, we investigated the association between the body mass index and ipilimumab treatment response in patients with metastatic melanoma. Patients with metastatic melanoma who received a monotherapy of up to 4 doses of ipilimumab (3 mg/kg) every 3 weeks from 2011 to 2014 in three major hospitals in Austria were included. Patients were classified into two groups: normal group (BMI<25) and overweight group (BMI≥25).

results40 patients had a normal BMI, and 36 had a BMI above normal. Patients with a BMI that was above normal showed significantly higher response rates (p = 0.024, χ2), and lower likelihood of brain metastases (p = 0.012, χ2). No differences were found between both groups with respect to gender (p = 0.324, χ2), T-stage (p = 0.197, χ2), or the occurrence of side effects (p = 0.646, χ2). Patients with a BMI above normal showed a trend towards longer overall survival (p = 0.056, Log-Rank), but no difference was found regarding progression-free survival (p = 0.924, Log-Rank).

conclusionsThe BMI correlated with the response to ipilimumab treatment in a cohort of metastatic melanoma patients.

Indexed as

Antineoplastic Agents, ImmunologicalAustriaBody Mass IndexBrain NeoplasmsFemaleHumansIpilimumabMaleMelanomaNeoplasm StagingProgression-Free SurvivalRetrospective StudiesAntineoplastic Agents, ImmunologicalIpilimumab

Identifiers

PMID30273398
PMCPMC6166940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.